每(mei)經編輯｜葉峰(feng)    

每經編輯 葉峰

上(shang)海(hai)萊士(shi)(002252)2日發(fa)生(sheng)3筆大(da)(da)宗(zong)交易(yi)，成交價格(ge)為19.02元和19.73元，累計成交833萬股，合計成交金額1.61億元。本次大(da)(da)宗(zong)交易(yi)買入方有(you)(you)西南證(zheng)(zheng)(zheng)券(quan)(quan)股份(fen)(fen)有(you)(you)限(xian)公司深(shen)圳(zhen)深(shen)南大(da)(da)道證(zheng)(zheng)(zheng)券(quan)(quan)營業部(bu)(bu)、中信(xin)證(zheng)(zheng)(zheng)券(quan)(quan)股份(fen)(fen)有(you)(you)限(xian)公司上(shang)海(hai)環球金融中心證(zheng)(zheng)(zheng)券(quan)(quan)營業部(bu)(bu)，賣出方有(you)(you)國(guo)(guo)都證(zheng)(zheng)(zheng)券(quan)(quan)股份(fen)(fen)有(you)(you)限(xian)公司北京工體(ti)北路證(zheng)(zheng)(zheng)券(quan)(quan)營業部(bu)(bu)、國(guo)(guo)信(xin)證(zheng)(zheng)(zheng)券(quan)(quan)股份(fen)(fen)有(you)(you)限(xian)公司深(shen)圳(zhen)紅(hong)嶺中路證(zheng)(zheng)(zheng)券(quan)(quan)營業部(bu)(bu)、光大(da)(da)證(zheng)(zheng)(zheng)券(quan)(quan)股份(fen)(fen)有(you)(you)限(xian)公司深(shen)圳(zhen)深(shen)南大(da)(da)道證(zheng)(zheng)(zheng)券(quan)(quan)營業部(bu)(bu)。

2月3日，上(shang)海萊(lai)士發布(bu)了控股(gu)股(gu)東(dong)收購Biotest相關事項的(de)(de)公(gong)(gong)(gong)告，公(gong)(gong)(gong)告顯(xian)示，控股(gu)股(gu)東(dong)科瑞天(tian)(tian)(tian)(tian)誠(cheng)(cheng)(cheng)和萊(lai)士中(zhong)國通過(guo)其與(yu)其他投資人共同投資設(she)立(li)(li)的(de)(de)香港(gang)公(gong)(gong)(gong)司TIANCHENGINTERNATIONAL INVESTMENT LIMITED（“天(tian)(tian)(tian)(tian)誠(cheng)(cheng)(cheng)國際投資”），已經(jing)于2018年(nian)1月31日完(wan)成(cheng)了對德(de)國上(shang)市公(gong)(gong)(gong)司BiotestAG（“Biotest”）的(de)(de)公(gong)(gong)(gong)開要約(yue)收購。收購完(wan)成(cheng)后，天(tian)(tian)(tian)(tian)誠(cheng)(cheng)(cheng)國際投資所(suo)設(she)立(li)(li)的(de)(de)Tiancheng（Germany）Pharmaceutical HoldingsAG（天(tian)(tian)(tian)(tian)誠(cheng)(cheng)(cheng)（德(de)國）制藥控股(gu)股(gu)份公(gong)(gong)(gong)司，“天(tian)(tian)(tian)(tian)誠(cheng)(cheng)(cheng)德(de)國”）持有Biotest公(gong)(gong)(gong)司普通股(gu)約(yue)89.88%，優(you)先股(gu)約(yue)1.08%。

資料顯(xian)示，BiotestAG是一家(jia)具有70年血(xue)(xue)液(ye)制(zhi)(zhi)品制(zhi)(zhi)造經驗的(de)(de)全球性(xing)全產(chan)(chan)業(ye)鏈血(xue)(xue)液(ye)制(zhi)(zhi)品公(gong)司，公(gong)司總部位于德國黑森州德賴埃希(xi)，現有業(ye)務(wu)(wu)主要為血(xue)(xue)漿采集(ji)與血(xue)(xue)液(ye)制(zhi)(zhi)品的(de)(de)生產(chan)(chan)和銷售(shou)，其中(zhong)血(xue)(xue)液(ye)制(zhi)(zhi)品包括人血(xue)(xue)白(bai)蛋白(bai)、免疫球蛋白(bai)和凝血(xue)(xue)因子三(san)大類。2016年度，Biotest持續經營(ying)業(ye)務(wu)(wu)收入約(yue)5.53億(yi)歐元(yuan)，經調整(zheng)的(de)(de)EBITDA（息稅折(zhe)舊(jiu)及攤銷前利潤）約(yue)1.08億(yi)歐元(yuan)，主營(ying)業(ye)務(wu)(wu)收入居(ju)全球同行業(ye)第(di)五。

公(gong)司表示，為維護上(shang)市公(gong)司及其股(gu)東(dong)利益(yi)，控(kong)股(gu)股(gu)東(dong)科瑞天(tian)誠(cheng)和(he)萊(lai)士中國計劃在符(fu)合相關(guan)法律法規要(yao)求(qiu)(qiu)的(de)前提下(xia)，未來擇機將Biotest整體或相關(guan)業務、資產注入上(shang)海萊(lai)士。如上(shang)海萊(lai)士認為該資產不符(fu)合公(gong)司的(de)長(chang)遠發展戰(zhan)略要(yao)求(qiu)(qiu)，主動提出(chu)放棄(qi)或不接受該資產或股(gu)權(quan)，科瑞天(tian)誠(cheng)和(he)萊(lai)士中國承諾將向第三方(fang)轉讓其間接持有(you)的(de)Biotest的(de)資產或股(gu)權(quan)。

（本文內容(rong)不構成(cheng)任何(he)投資建(jian)議。投資者據(ju)此操(cao)作，風險自(zi)擔。）